Cifc Llc Cmn Shs (CIFC) 7.29 $CIFC CIFC LLC Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cifc Llc Cmn Shs (CIFC) 7.29 $CIFC

CIFC LLC Announces First Quarter of 2016 Results and a Quarterly Distribution of $0.25
GlobeNewswire - Fri May 06, 7:15AM CDT
CIFC LLC (NASDAQ:CIFC) ("CIFC" or the "Company" today announced its results for the first quarter ended March 31, 2016.
CIFC: 7.29 (+0.48)

CIFC Awarded Four 2015 Manager Awards by Creditflux Including "Creditflux Manager of the Year"
GlobeNewswire - Thu May 05, 3:02PM CDT
CIFC LLC (NASDAQ:CIFC), and its subsidiaries (collectively, "CIFC" or the "Company" was pleased to accept four Creditflux Manager Awards for 2015 in London last night.
CIFC: 7.29 (+0.48)

CIFC LLC Announces Fourth Quarter and Full Year of 2015 Results and a $0.34 Distribution
GlobeNewswire - Mon Mar 21, 4:00PM CDT
CIFC LLC (NASDAQ:CIFC) ("CIFC" or the "Company" today announced its results for the fourth quarter and year ended December 31, 2015.
CIFC: 7.29 (+0.48)

CIFC Wins Private Debt Investor's CLO Manager of the Year, Americas, for the Third Year in a Row
GlobeNewswire - Wed Mar 02, 3:01PM CST
CIFC LLC (NASDAQ:CIFC), and its subsidiaries (collectively, "CIFC" or the "Company" is pleased to announce that it is the recipient of Private Debt Investor's 2015 Award for CLO Manager of the Year - Americas. This is the third year in a row the firm has received this honor.
CIFC: 7.29 (+0.48)

CIFC Engages JPMorgan to Assist in Exploration of Strategic Alternatives
GlobeNewswire - Thu Jan 28, 8:00AM CST
CIFC LLC (NASDAQ:CIFC) and its subsidiaries (collectively "CIFC" or the "Company" announced the engagement of JPMorgan Securities LLC to assist the Company and management in exploring a range of strategic alternatives to enhance shareholder value and to capitalize on its industry-leading platform. Those alternatives may include a sale of the Company or the sale of a stake in the Company to a strategic investor with the objective of accelerating the Company's existing growth and diversification initiatives.
CIFC: 7.29 (+0.48)

CIFC Completes $510.5 Million Collateralized Loan Obligation ("CLO"
GlobeNewswire - Tue Nov 24, 4:45PM CST
CIFC Corp. (NASDAQ:CIFC) and its subsidiaries (collectively "CIFC" or the "Company" announced the closing of a new CIFC-managed CLO, CIFC Funding 2015-V, Ltd., representing $510.5 million of par value of notes and approximately $500.0 million of new assets under management. The transaction was led by Credit Suisse Securities (USA) LLC and supported by 14 institutional investors, five of which were first-time investors with CIFC.
CIFC: 7.29 (+0.48)

CIFC Corp. Announces Third Quarter of 2015 Results and a Quarterly Dividend
GlobeNewswire - Thu Nov 12, 8:00AM CST
CIFC Corp. (NASDAQ:CIFC) ("CIFC" or the "Company" today announced its results for the third quarter ended September 30, 2015.
CIFC: 7.29 (+0.48)

CIFC Corp. Announces the Closing of $40 Million Senior Notes Offering
GlobeNewswire - Mon Nov 02, 4:09PM CST
CIFC Corp. (NASDAQ:CIFC) ("CIFC" today announced the closing of its previously announced offering of $40 million aggregate principal amount of unsecured senior notes due 2025. The notes will pay interest semi-annually at a rate of 8.50% per annum and will be non-callable for five years.
CIFC: 7.29 (+0.48)

CIFC Appoints Senior Portfolio Manager of Structured Products
GlobeNewswire - Mon Oct 19, 4:07PM CDT
CIFC Corp. (NASDAQ:CIFC), and its subsidiaries (collectively "CIFC" or the "Company" today announced that Robert J. Klein has joined the firm as Senior Portfolio Manager and Managing Director, Structured Products, and will lead the firm's structured products portfolios. Mr. Klein reports to Co-Presidents Oliver Wriedt and Steve Vaccaro and will join the firm's Operating Committee.
CIFC: 7.29 (+0.48)

CIFC Corp. Announces Second Quarter of 2015 Results and a Quarterly Dividend
PR Newswire - Fri Aug 07, 3:30PM CDT
CIFC Corp. (NASDAQ: CIFC) ("CIFC" or the "Company" today announced its results for the second quarter ended June 30, 2015.
CIFC: 7.29 (+0.48)

CIFC Asset Management Awarded "Best High Yield Fund" by Creditflux
PR Newswire - Tue May 19, 3:18PM CDT
CIFC Asset Management, a subsidiary of publicly listed alternative credit manager CIFC Corp. (NASDAQ: CIFC), is honored to accept Creditflux's 2015 Award for Best High Yield Fund. The firm received the honor at a ceremony in London on May 6.
CIFC: 7.29 (+0.48)

CIFC Corp. Announces First Quarter of 2015 Results and a Quarterly Dividend
PR Newswire - Wed May 06, 3:33PM CDT
CIFC Corp. (NASDAQ: CIFC) ("CIFC" or the "Company" today announced its results for the first quarter ended March 31, 2015.
CIFC: 7.29 (+0.48)

Quarterly Report Card: Special Research on Cellular Biomedicine, CIFC Corp., Consumer Portfolio Services, Credit Acceptance, and Home Loan Servicing
PR Newswire - Tue Apr 21, 8:54AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CIFC: 7.29 (+0.48), CACC: 184.47 (+7.11), CPSS: 3.90 (+0.10), CBMG: 13.71 (-0.26), HLSS: 0.67 (-16.51)

CIFC Appoints New Head of Investor Relations as Platform, Offerings Expand
PR Newswire - Mon Apr 20, 4:18PM CDT
CIFC Corp. (NASDAQ: CIFC), a leading relative-value credit manager, today announced that Ruth Lane has joined the firm as Head of Investor Relations, a newly created position.
CIFC: 7.29 (+0.48)

CIFC Credit Funds Completes GIPS® Verification
PR Newswire - Tue Apr 14, 3:48PM CDT
CIFC Corp. (NASDAQ: CIFC) announced today that CIFC Credit Funds claims compliance with the Global Investment Performance Standards (GIPS®) and has been independently verified since inception in November 2012 through December 31, 2014.
CIFC: 7.29 (+0.48)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 22

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 27

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Expands Tax Advisory Team with New Experts

Updated Category News Views 199

FTI Consulting Strengthens Tax Advisory Team FTI Consulting, Inc. (NYSE: FCN) has announced the strategic enhancement of its Tax Advisory team within the EMEA region through the recruitment of two highly experienced professionals. This move reflects the company's commitment to providing top-tier advisory services amidst the complexities of the global tax environment. New...

Continue Reading
Cingulate Inc. Unveils Q1 Financial Highlights and Future Plans

Updated Category News Views 148

Cingulate Inc. Reports First Quarter Financial Results Cingulate Inc. (NASDAQ: CING), a biopharmaceutical entity known for its innovative Precision Timed Release™ (PTR™) drug delivery technology, has recently unveiled its financial results for the first quarter. The report sheds light on several important developments concerning their lead assets for ADHD and anxiety....

Continue Reading
Innovative Partnership Propels Sen-Jam Pharmaceutical's Future

Updated Category News Views 106

Strategic Partnership to Enhance Phase 3 Trial for SJP-001 In a significant move, Sen-Jam Pharmaceutical has announced a promising partnership with TASK Clinical, a renowned global contract research organization (CRO), aimed at funding two-thirds of the upcoming Phase 3 clinical trial for its lead candidate, SJP-001. This equity-backed collaboration is not only innovative...

Continue Reading
Exploring the Future of Solar Energy: Insights from EnergySage

Updated Category News Views 231

EnergySage's Solar & Storage Marketplace Report Highlights EnergySage, a trusted name in solar market analysis, has released its latest report, which delves into the current dynamics of the solar and storage marketplace. This comprehensive analysis examines trends that are influencing the future of the industry, particularly in light of recent policy shifts. Residential...

Continue Reading
Investors' Rights: Explore Possible Violations for SCS, HLVX and Others

Updated Category News Views 166

Investigation into Potential Shareholder Violations Halper Sadeh LLC, a well-known law firm advocating for investor rights, is currently investigating several companies due to potential breaches of federal securities laws and fiduciary duties to their shareholders. Steelcase Inc. (SCS) Steelcase Inc. is reportedly undergoing a transaction involving the sale to HNI...

Continue Reading